Phase IIb Aviator Trial Shows High Viral Response Rates In Patient Types With HCV Genotype 1
Tuesday, April 23, 2013 - 14:54
in Health & Medicine
Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment and in patients who had previously failed treatment with pegylated interferon and ribavirin (null responders). read more